Journal: Blood
This study examined survival outcomes in advanced mycosis fungoides (MF) and Sézary syndrome (SS), conditions with poor overall survival (OS) under 5 years.
Conducted across 46 international centers, the PROCLIPI study enrolled 552 patients with advanced-stage MF/SS to develop a more accurate prognostic tool than current staging.
Five-year OS varied across stages but did not consistently worsen with advancing stage.
Key adverse prognostic factors identified at diagnosis included:
- N3 lymph node status
- Age over 60
- Elevated serum lactate dehydrogenase
- Large-cell transformation in the skin
Incorporating these factors into the Cutaneous Lymphoma International Prognostic Index (CLIPI) effectively stratified patients into low-, intermediate-, and high-risk groups, with corresponding 5-year OS rates of 63.3%, 44.7%, and 18.3%.
The CLIPI offers improved risk stratification to guide treatment decisions and potentially improve outcomes for advanced MF/SS patients.